$6.87
3.10% today
Nasdaq, Aug 25, 06:18 pm CET
ISIN
US35104E1001
Symbol
FDMT

4D Molecular Therapeutics Inc Stock price

$7.09
+2.59 57.56% 1M
+2.57 56.86% 6M
+1.52 27.29% YTD
-7.38 51.00% 1Y
-1.24 14.89% 3Y
-15.91 69.17% 5Y
-15.91 69.17% 10Y
-15.91 69.17% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.24 3.50%
ISIN
US35104E1001
Symbol
FDMT
Industry

Key metrics

Basic
Market capitalization
$331.1m
Enterprise Value
$37.9m
Net debt
positive
Cash
$293.2m
Shares outstanding
46.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
11,037.4 | 89.3
EV/Sales
1,263.0 | 10.2
EV/FCF
negative
P/B
0.8
Financial Health
Equity Ratio
91.1%
Return on Equity
-31.5%
ROCE
-50.2%
ROIC
-129.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$30.0k | $3.7m
EBITDA
$-212.4m | $-231.1m
EBIT
$-220.3m | $-229.4m
Net Income
$-196.1m | $-173.9m
Free Cash Flow
$-169.8m
Growth (TTM | estimate)
Revenue
-99.9% | 9,170.0%
EBITDA
-4.6% | -27.6%
EBIT
-6.2% | -22.2%
Net Income
-9.9% | -8.1%
Free Cash Flow
-94.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-643,472.7% | -6,231.7%
EBIT
-667,654.6%
Net
-594,375.8% | -4,690.2%
Free Cash Flow
-514,584.9%
More
EPS
$-3.5
FCF per Share
$-3.6
Short interest
8.3%
Employees
227
Rev per Employee
$0.0
Show more

Is 4D Molecular Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

4D Molecular Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a 4D Molecular Therapeutics Inc forecast:

13x Buy
76%
3x Hold
18%
1x Sell
6%

Analyst Opinions

17 Analysts have issued a 4D Molecular Therapeutics Inc forecast:

Buy
76%
Hold
18%
Sell
6%

Financial data from 4D Molecular Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.03 0.03
100% 100%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 50 50
25% 25%
167,133%
- Research and Development Expense 170 170
6% 6%
567,400%
-212 -212
5% 5%
-707,833%
- Depreciation and Amortization 7.98 7.98
79% 79%
26,600%
EBIT (Operating Income) EBIT -220 -220
6% 6%
-734,420%
Net Profit -196 -196
10% 10%
-653,800%

In millions USD.

Don't miss a Thing! We will send you all news about 4D Molecular Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

4D Molecular Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about 5 hours ago
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor c...
Neutral
GlobeNewsWire
10 days ago
EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on August 12, 2025, the compensation committee of the Company's boar...
Neutral
GlobeNewsWire
14 days ago
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q2 2025 financial results, provided operational highlights and outlined ex...
More 4D Molecular Therapeutics Inc News

Company Profile

4D Molecular Therapeutics, Inc. engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. It offers products for optalmology, cardiology, and pulmonology. The company was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Head office United States
CEO David Kirn
Employees 227
Founded 2013
Website 4dmoleculartherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today